A high-throughput platform for proteomic profiling with next-generation sequencing (NGS) readout identified early biomarkers for type 2 diabetes and predicted who will best respond to therapeutic intervention.
There is a range of technologies that provide spatial resolution for expressed genes or proteins and allow scientists to look at even the best-characterized biological mechanisms with fresh eyes. No single platform is best for all studies, however; each researcher must consider various factors to choose the best technology for their lab.
Recent findings of known and novel SARS-CoV-2 variants underscore the importance of next-generation-sequencing (NGS)-based epidemiology and surveillance research, alongside the need for full genomic coverage of the SARS-CoV-2 virus for NGS studies.
New research from Biognosys and collaborators, presented at the 2021 ASCO and AACR conferences, shows how next-generation proteomics can help to predict both outcomes and adverse events from immunotherapy.
Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types.
In recent years, the field of proteomics has undergone a transformation, enabling quantitative analysis of more than 10,000 proteins across thousands of samples, while advances in structural chemoproteomics allow researchers to map drug binding sites with unprecedented resolution. These next-generation proteomics approaches are driving significant progress in precision oncology.